开拓药业-B(09939.HK)与迈百瑞订战略合作 开发生物大分子药物
开拓药业-B(09939.HK)宣布,公司与迈百瑞国际生物医药签署战略合作协议,双方就生物大分子药物的研发与生产展开全方位合作。双方合作的第一个项目GT90008(PD-L1/TGF-β双抗)的CMC工作将正式启动。通过此次强强联合,将加速开拓药业在生物大分子药物领域的研发进程,为全球病患提供更多更好的解决方案。
开拓药业创始人、董事长兼首席执行官童友之称,开拓药业正在积极拓展生物药领域的战略布局,GT90008项目是公司的第一个双抗项目,相信迈百瑞公司「一站式」CDMO服务能力能够高质量的推动GT90008项目的研发进程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.